Information Provided By:
Fly News Breaks for June 13, 2016
VCYT, NVTA, ILMN, CDNA
Jun 13, 2016 | 07:53 EDT
Leerink analyst Dan Leonard expects several diagnostics stocks to underperform following proposed price cuts or low initial reimbursement rates by the Centers for Medicare and Medicaid Services, or CMS, for diagnostic tests. If finalized, the preliminary pricing would negatively impact CareDx (CDNA), Veracyte (VCYT), and InVitae (NVTA), the analyst tells investors in a research note, adding that he also sees an indirect negative read-through for Illumina (ILMN).
News For CDNA;ILMN;NVTA;VCYT From the Last 2 Days
There are no results for your query CDNA;ILMN;NVTA;VCYT